© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Mantle Cell Lymphoma
Exploring Unmet Needs and BTK Inhibitors in the MCL Population
August 20, 2020
Nilanjan Ghosh, MD, discusses the current unmet needs in mantle cell lymphoma and how Bruton’s tyrosine kinase inhibitors are being looked at to fill that need for patients with high-risk disease in the first line.
Expert Reviews Treatment Landscape for Patients With Mantle Cell Lymphoma
August 19, 2020
Lori A. Leslie, MD, discusses the current treatment options for patients with mantle cell lymphoma.
Meta-Analysis Highlights Commonly Mutated Genes in Mantle Cell Lymphoma
August 17, 2020
The frequency of mutations in patients with mantle cell lymphoma has a tendency to increase at clinical turning points like disease relapse and progression compared with at the time of diagnosis, according to a systemic review and meta-analysis.
Temsirolimus Plus R-CHOP Most Feasible of Chemotherapy Combinations in R/R Mantle Cell Lymphoma
August 12, 2020
Combining temsirolimus with a chemotherapy regimen as treatment of patients with relapsed or refractory mantle cell lymphoma is feasible, according to the phase 1b T3 clinical trial.
FDA Approves KTE-X19 CAR T-Cell Therapy for R/R Mantle Cell Lymphoma
July 24, 2020
The FDA has approved brexucabtagene autoleucel for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Discussing How to Treat Patients With Mantle Cell Lymphoma
July 23, 2020
Lori A. Leslie, MD, discusses options for patients with relapsed/refractory mantle cell lymphoma.
CAR T-Cell Therapy Offers Potential Solution for Relapse in MCL, But With Toxicity Risk
July 22, 2020
In a presentation during the 2020 Debates and Didactics in Hematology and Oncology conference, Amelia A. Langston, MD, explained the issues with treating patients with relapsed mantle cell lymphoma and how the integration of chimeric antigen receptor T-cell therapy can be a solution to the problem.
Bortezomib Consolidation or Maintenance Extends Survival With R-CHOP in MCL
July 09, 2020
The addition of bortezomib consolidation therapy or bortezomib maintenance to the immunochemotherapy regimen rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone improved progression-free survival in patients with mantle cell lymphoma in the post-transplant setting, according to a comparative analysis, CALGB/Alliance 50403 trial.
CLL and MCL Survival Benefit From Umbralisib Plus Ibrutinib Holds Up in 4-Year Follow-Up
July 08, 2020
In an interview with Targeted Oncology, Matthew Davids, MD, MMSc, discussed the long-term follow-up results of ibrutinib in combination with umbralisib as treatment of patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Novel BTK Inhibitor Appears Promising in Mantle Cell Lymphoma and Other NHLs
July 02, 2020
In an interview with Targeted Oncology, Gaël Roué, PhD, discussed the rationale for evaluating TG-1701 in combination with ublituximab and umbralisib in ibrutinib-resistant MCL.